SpineGuard Obtains U.S. Patent for Spinal Ultrasound Technology
The designer of DSG surgical guidance technology has had validated by the U.S. Patent Office an ultrasound technology intended to prepare the placement of spinal implants. The company indicates it now wishes to establish a partnership for its commercial exploitation.
SpineGuard announced on August 24, 2026, that it had obtained validation of a new U.S. patent by the USPTO (U.S. Patent and Trademark Office). This patent covers a robotically-assisted ultrasound technology used to determine the entry point and pedicle trajectory from the bone surface of the spinal column.
According to the company, this technology implements ultrasound to determine, without using X-rays, the entry point and drilling direction from the posterior surface of the bone. It is presented as a complement to SpineGuard's DSG technology for detecting bone breach in real time, employed before the drill penetrates the bone.
Search for an Industrial Partner for Commercial Exploitation
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Stéphane Bette, Delegated Chief Executive Officer and Co-founder of SpineGuard, linked this patent grant to a presentation at the CFA Congress in April and the defense of a science thesis in December. He indicated that the next step consists of seeking an industrial partner to commercially exploit the patent.
The company specifies that its intellectual property portfolio currently comprises 11 patent families as well as 3 registered trademarks, in regions including Europe, the United States, China and Japan. It recalls that more than 110,000 surgeries have been secured to date thanks to its DSG technology.
SectorDispositifs médicaux et optique›Dispositifs médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 1,4 millions d'euros
Quarterly revenue: 1,4 millions d'euros
EBITDA: -1 millions d'euros
Net income: -1,2 millions d'euros
Guidance from the release
operational breakeven in the fourth quarter of 2026 has been its top financial priority since June 2024
Risks mentioned
U.S. business model transition resulted in 47% revenue decline in the region
Tight cash position of 694 K€ as of June 30, 2026 requires financing through Q2 2027
Inventory build-up and transition costs significantly impacted H1 2026 profitability
Opportunities identified
Strong European sales momentum with 17% growth during H1 2026
Strategic partnership with Omnia Medical to expand U.S. market access via their hospital network and implant portfolio
New product developments including PsiFGuard sacroiliac joint fusion system and smart screw with DSG sensor targeting regulatory approval in H1 2027
Outlook / guidance
Management commentary: achieve operational breakeven in the fourth quarter of the 2026
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
